{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T06:40:23Z","timestamp":1721025623588},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>During radioactive Iodine-125 seed implantation (RISI), Iodine-125 radionuclide is implanted directly into a lesion and kills tumor cells by steadily emitting radiation. In our study, we analyzed the adverse effects of RISI for thoracic malignancy, and investigated the safety, dosage, and adverse effects of RISI for these cases. Between June 2007 and January 2018, 77 patients with thoracic recurrent and\/or metastatic tumors who underwent CT-guided RISI were enrolled. Radiation-related adverse effects were analyzed, including pneumonia, esophagitis, hemorrhage, fistula, skin injury, heart injury, and spinal cord injury. We used the Common Terminology Criteria for Adverse Events (CTCAE) v4.03 to evaluate adverse effects and analyzed the relationship between adverse effects and dosimetric parameters of organs at risk (OAR), including D0.1cc, D2cc, Dmean, and V20. The results of the study were as follows: The median follow-up period was 11 months. The median postoperative dose (D90) was 122\u2009Gy (45.7\u2013241.8\u2009Gy). Three patients (3.9%) showed radiation pneumonitis of grade \u22652. Two patients (2.6%) showed radiation-induced esophagitis of grade \u22652. One patient (1.3%) showed an esophageal fistula. Two patients (2.6%) had a tracheal fistula. Five patients (6.5%) had radiation-related skin reactions. One patient (1.3%) reported chest wall pain, while three (3.9%) showed hemoptysis. No patients showed radiation myelitis or cardiotoxicity. The mean D2cc of organs at risk were 165.7\u2009Gy (lung), 10.61\u2009Gy (esophagus), 10.25\u2009Gy (trachea), 18.07\u2009Gy (blood vessel), 12.64\u2009Gy (heart), 14.77\u2009Gy (spinal cord), 17.47\u2009Gy (skin). Dosimetric parameters, such as D0.1cc, D2cc and Dmean, were higher in patients with toxic reactions (above the upper limit of 95% confidence interval among the overall data). Chi-square test showed that skin D0.1cc\u2009&gt;\u2009600\u2009Gy, D2cc\u2009&gt;\u2009500\u2009Gy, and Dmean &gt;90\u2009Gy were associated with grade \u22652 radiation dermatitis (p\u2009&lt;\u20090.05), but no clear dose-toxicity correlation was found in other OARs. So, we concluded that the overall incidence of toxicity and adverse effects from RISI for the treatment of thoracic tumors is low. The dose-toxicity characteristics have not been fully defined. Doses within the upper limit of the 95% confidence interval may be considered safe. This was a retrospective analysis, and follow-up period was minimal, indicating possible limitations of this study.<\/jats:p>","DOI":"10.1038\/s41598-019-51458-5","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T11:22:28Z","timestamp":1571138548000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Radiation-related Adverse Effects of CT-guided Implantation of 125I Seeds for Thoracic Recurrent and\/or Metastatic Malignancy"],"prefix":"10.1038","volume":"9","author":[{"given":"Zhe","family":"Ji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuliang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuxin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinghong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,15]]},"reference":[{"key":"51458_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4103\/jcrt.JCRT_888_17","volume":"14","author":"J Wang","year":"2018","unstructured":"Wang, J. et al. Expert consensus statement on computed tomography-guided (125)I radioactive seeds permanent interstitial brachytherapy. Journal of cancer research and therapeutics 14, 12\u201317, https:\/\/doi.org\/10.4103\/jcrt.JCRT_888_17 (2018).","journal-title":"Journal of cancer research and therapeutics"},{"key":"51458_CR2","doi-asserted-by":"publisher","unstructured":"Zhang, F. et al. Chinese Expert Consensus Workshop Report: Guideline for permanent iodine-125 seed implantation of primary and metastatic lung tumors. Thoracic Cancer 0, https:\/\/doi.org\/10.1111\/1759-7714.12912 (2018).","DOI":"10.1111\/1759-7714.12912"},{"key":"51458_CR3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrurol.2017.76","volume":"14","author":"NG Zaorsky","year":"2017","unstructured":"Zaorsky, N. G. et al. The evolution of brachytherapy for prostate cancer. Nature reviews. Urology 14, 415\u2013439, https:\/\/doi.org\/10.1038\/nrurol.2017.76 (2017).","journal-title":"Nature reviews. Urology"},{"key":"51458_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-11-60","volume":"11","author":"L Zhu","year":"2013","unstructured":"Zhu, L. et al. An investigation of 125I seed permanent implantation for recurrent carcinoma in the head and neck after surgery and external beam radiotherapy. World journal of surgical oncology 11, 60, https:\/\/doi.org\/10.1186\/1477-7819-11-60 (2013).","journal-title":"World journal of surgical oncology"},{"key":"51458_CR5","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1016\/j.ejrad.2013.05.037","volume":"82","author":"Q Huang","year":"2013","unstructured":"Huang, Q. et al. Computed tomographic-guided iodine-125 interstitial implants for malignant thoracic tumors. European journal of radiology 82, 2061\u20132066, https:\/\/doi.org\/10.1016\/j.ejrad.2013.05.037 (2013).","journal-title":"European journal of radiology"},{"key":"51458_CR6","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/1756-9966-32-106","volume":"32","author":"H Wang","year":"2013","unstructured":"Wang, H. et al. The investigation of 125I seed implantation as a salvage modality for unresectable pancreatic carcinoma. Journal of experimental & clinical cancer research: CR 32, 106, https:\/\/doi.org\/10.1186\/1756-9966-32-106 (2013).","journal-title":"Journal of experimental & clinical cancer research: CR"},{"key":"51458_CR7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00384-008-0628-4","volume":"24","author":"JJ Wang","year":"2009","unstructured":"Wang, J. J. et al. Interstitial permanent implantation of 125I seeds as salvage therapy for re-recurrent rectal carcinoma. International journal of colorectal disease 24, 391\u2013399, https:\/\/doi.org\/10.1007\/s00384-008-0628-4 (2009).","journal-title":"International journal of colorectal disease"},{"issue":"Suppl 2","key":"51458_CR8","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.4103\/0019-509x.151999","volume":"51","author":"G Jiang","year":"2015","unstructured":"Jiang, G. et al. Computed tomography-guided iodine-125 interstitial implantation as an alternative treatment option for lung cancer. Indian journal of cancer 51(Suppl 2), e9\u201312, https:\/\/doi.org\/10.4103\/0019-509x.151999 (2015).","journal-title":"Indian journal of cancer"},{"key":"51458_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s12032-014-0395-8","volume":"32","author":"W Li","year":"2015","unstructured":"Li, W. et al. Iodine-125 brachytherapy improved overall survival of patients with inoperable stage III\/IV non-small cell lung cancer versus the conventional radiotherapy. Medical oncology (Northwood, London, England) 32, 395, https:\/\/doi.org\/10.1007\/s12032-014-0395-8 (2015).","journal-title":"Medical oncology (Northwood, London, England)"},{"key":"51458_CR10","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.3892\/ol.2015.3039","volume":"9","author":"Q Zhang","year":"2015","unstructured":"Zhang, Q., Wang, D. Q. & Wu, Y. F. Sodium glycididazole enhances the efficacy of combined iodine-125 seed implantation and chemotherapy in patients with non small-cell lung cancer. Oncology Letters 9, 2335\u20132340, https:\/\/doi.org\/10.3892\/ol.2015.3039 (2015).","journal-title":"Oncology Letters"},{"key":"51458_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1118\/1.597458","volume":"22","author":"R Nath","year":"1995","unstructured":"Nath, R. et al. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Medical physics 22, 209\u2013234 (1995).","journal-title":"Medical physics"},{"key":"51458_CR12","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1118\/1.1646040","volume":"31","author":"MJ Rivard","year":"2004","unstructured":"Rivard, M. J. et al. Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations. Medical physics 31, 633\u2013674 (2004).","journal-title":"Medical physics"},{"key":"51458_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.brachy.2011.07.005","volume":"11","author":"BJ Davis","year":"2012","unstructured":"Davis, B. J. et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy 11, 6\u201319, https:\/\/doi.org\/10.1016\/j.brachy.2011.07.005 (2012).","journal-title":"Brachytherapy"},{"key":"51458_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.radonc.2007.01.014","volume":"83","author":"C Salembier","year":"2007","unstructured":"Salembier, C. et al. Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO\/EAU\/EORTC recommendations on prostate brachytherapy. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology 83, 3\u201310, https:\/\/doi.org\/10.1016\/j.radonc.2007.01.014 (2007).","journal-title":"Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology"},{"key":"51458_CR15","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/About.html (2017)."},{"key":"51458_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European journal of cancer (Oxford, England: 1990) 45, 228\u2013247, https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026 (2009).","journal-title":"European journal of cancer (Oxford, England: 1990)"},{"key":"51458_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brachy.2015.09.006","volume":"15","author":"A Stewart","year":"2016","unstructured":"Stewart, A. et al. American Brachytherapy Society consensus guidelines for thoracic brachytherapy for lung cancer. Brachytherapy 15, 1\u201311, https:\/\/doi.org\/10.1016\/j.brachy.2015.09.006 (2016).","journal-title":"Brachytherapy"},{"key":"51458_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13014-018-0959-4","volume":"13","author":"Y Jiang","year":"2018","unstructured":"Jiang, Y. et al. Side effects of CT-guided implantation of (125)I seeds for recurrent malignant tumors of the head and neck assisted by 3D printing non co-planar template. Radiation oncology (London, England) 13, 18, https:\/\/doi.org\/10.1186\/s13014-018-0959-4 (2018).","journal-title":"Radiation oncology (London, England)"},{"key":"51458_CR19","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.ijrobp.2009.09.070","volume":"78","author":"P Kelly","year":"2010","unstructured":"Kelly, P. et al. Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation. International journal of radiation oncology, biology, physics 78, 1387\u20131393, https:\/\/doi.org\/10.1016\/j.ijrobp.2009.09.070 (2010).","journal-title":"International journal of radiation oncology, biology, physics"},{"key":"51458_CR20","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.ijrobp.2014.01.012","volume":"88","author":"M Trovo","year":"2014","unstructured":"Trovo, M. et al. Stereotactic body radiation therapy for re-irradiation of persistent or recurrent non-small cell lung cancer. International journal of radiation oncology, biology, physics 88, 1114\u20131119, https:\/\/doi.org\/10.1016\/j.ijrobp.2014.01.012 (2014).","journal-title":"International journal of radiation oncology, biology, physics"},{"key":"51458_CR21","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.cllc.2015.11.008","volume":"17","author":"P Li","year":"2016","unstructured":"Li, P. et al. Single Nucleotide Polymorphisms in CBLB, a Regulator of T-Cell Response, Predict Radiation Pneumonitis and Outcomes After Definitive Radiotherapy for Non-Small-Cell Lung Cancer. Clinical lung cancer 17, 253\u2013262.e255, https:\/\/doi.org\/10.1016\/j.cllc.2015.11.008 (2016).","journal-title":"Clinical lung cancer"},{"key":"51458_CR22","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.ijrobp.2013.11.241","volume":"88","author":"D Georg","year":"2014","unstructured":"Georg, D. et al. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy. International journal of radiation oncology, biology, physics 88, 715\u2013722, https:\/\/doi.org\/10.1016\/j.ijrobp.2013.11.241 (2014).","journal-title":"International journal of radiation oncology, biology, physics"},{"key":"51458_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1118\/1.597458","volume":"22","author":"R Nath","year":"1995","unstructured":"Nath, R. et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Medical Physics 22, 209\u2013234, https:\/\/doi.org\/10.1118\/1.597458 (1995).","journal-title":"Medical Physics"},{"key":"51458_CR24","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.radonc.2013.02.002","volume":"106","author":"JD Evans","year":"2013","unstructured":"Evans, J. D. et al. Aortic dose constraints when reirradiating thoracic tumors. Radiother Oncol 106, 327\u2013332, https:\/\/doi.org\/10.1016\/j.radonc.2013.02.002 (2013).","journal-title":"Radiother Oncol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51458-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51458-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51458-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T14:39:55Z","timestamp":1671287995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51458-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["51458"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-51458-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,15]]},"assertion":[{"value":"11 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"14803"}}